NCT05420324

A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma

A Multicenter, Single-arm, Open-label Phase II Study to Evaluate the Efficacy and Safety of YH003 in Combination with Pebolizumab and Albumin Paclitaxel in First-line Treatment of Patients with Unresectable/metastatic Mucosal Melanoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Eucure (Beijing) Biopharma Co., Ltd · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a multicenter, single-arm, open-label phase II study to assess the efficacy and safety of YH003 in combination with pembrolizumab and nab-paclitaxel in the first-line treatment of patients with unresectable/metastatic mucosal melanoma.

Conditions

• Mucosal Melanoma

Interventions

Type	Name	Description
DRUG	YH003	YH003 will be administered intravenously over 30 minutes every 21-day cycle.
DRUG	Pembrolizumab	Pembrolizumab will be administered intravenously over 30 minutes every 21-day cycle.
DRUG	albumin paclitaxel	Albumin paclitaxel will be administered intravenously over 30 minutes every 21-day cycle.

Timeline

• Start date: 2022-06-13
• Primary completion: 2024-03-04
• Completion: 2024-03-04
• First posted: 2022-06-15
• Last updated: 2025-01-06

Locations

12 sites across 1 country: China